Skip to contentC
Cumberland Pharmaceuticals Inc
C
CPIXCumberland Pharmaceuticals Inc Q2 2022 · 10-Q
Revenue$10.30M$10.30M+13.7% vs Q2 2021 Net Income-$1.34M-$1.34MN/M vs Q2 2021 EPS Diluted-$0.09-$0.09N/M vs Q2 2021 Operating Income-$1,846,538N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cumberland Pharmaceuticals Inc · CIK 1087294 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$2,193,281−18.3% Margins · derivedOperating margin-17.9%−2.1 pt vs Q2 2021
Net margin-13.0%−26.5 pt vs Q2 2021
ended Jun 30, 2022 · filed Aug 12, 2022 · 43 d after period end